Outset Medical, Inc.'s SEC filings document operating results, product and service revenue, gross margin, cash resources, and guidance for its dialysis technology business. Recent Form 8-K reports furnish earnings releases for the Tablo Hemodialysis System business and disclose material events such as FDA 510(k) clearance for the next-generation Tablo platform.
Proxy materials and current reports also cover governance and compensation matters, including board composition, director independence, committee appointments, executive compensation tables, pay-versus-performance disclosures, and equity awards. The filing record ties these disclosures to Outset’s capital structure, Nasdaq-listed common stock, and medical-device regulatory environment.
Bank of America Corporation filed a Schedule 13G reporting a beneficial ownership position in Outset Medical, Inc. common stock. The firm reports holding 950,558 shares, representing 5.2% of the outstanding common stock, based on 18,153,090 shares outstanding as of November 6, 2025.
All voting and dispositive power over these shares is described as shared, with no sole voting or dispositive authority. The filing is made on behalf of Bank of America and several wholly owned subsidiaries, and it states the shares were acquired and are held in the ordinary course of business, not to influence control of Outset Medical.
Outset Medical, Inc. reported that the U.S. Food and Drug Administration has granted 510(k) clearance for its next-generation Tablo hemodialysis platform. This clearance allows the updated system to be marketed in the United States under its cleared indications.
The company stated that it expects to begin shipping the next-generation Tablo platform to customers in the second quarter of 2026. Outset highlighted that future performance and impact of the product, as well as the timing of enhancements and new features, remain subject to various risks and uncertainties described in its SEC filings.
Outset Medical, Inc. executive Marc Nash reported two sales of company common stock. On January 20, 2026, he sold 5,375 shares at $5.12 per share, followed by a sale of 980 shares at $4.98 per share on January 21, 2026, all held directly.
The footnote explains these 6,355 shares were sold to cover partial tax withholding obligations tied to the vesting of 14,839 RSU-based shares granted on June 10, 2025, and that the transactions did not represent discretionary trades by Nash. After these sales, he directly owned 41,805 shares of Outset Medical common stock.
Outset Medical, Inc.'s General Counsel, John L. Brottem, reported automatic sales of company common stock to cover tax withholding on recently vested equity awards. On January 20, 2026, he sold 9,314 shares of common stock at $5.12 per share, leaving him with 36,957 shares beneficially owned. On January 21, 2026, he sold an additional 1,180 shares at $5.01 per share, resulting in 35,777 shares beneficially owned afterward.
The filing explains that these 10,494 shares were the required number sold to partially cover tax withholding tied to the vesting of 17,997 shares of common stock underlying RSUs granted to him on June 10, 2025. The sales were executed as a “sell to cover” transaction for tax purposes and are described as not discretionary trades by the reporting person.
Outset Medical, Inc. insider filing shows tax-related share sales by Chair and CEO Leslie Trigg. On January 20, 2026, Trigg sold 11,794 shares of common stock at $5.12 per share, followed by a sale of 2,120 shares at $5.05 per share on January 21, 2026.
According to the footnote, these transactions were the required number of shares sold to cover partial tax withholding obligations tied to the vesting of 32,552 RSU-based shares granted on June 10, 2025, executed as a "sell to cover" and not as discretionary trades. After these sales, Trigg directly beneficially owned 105,703 shares of common stock and indirectly held additional shares through trusts.
Outset Medical insider plans additional stock sale under Rule 144. The filing indicates that Leslie Trigg intends to sell 2,120 shares of Outset Medical common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of 10,696.59. The shares relate to equity compensation and are part of a broader pattern of recent sales.
The notice also reports prior sales over the past three months, including 916 shares on 11/17/2025, 1,795 shares on 01/07/2026, and 11,794 shares on 01/20/2026, for gross proceeds of 4,213.60, 7,664.65, and 60,385.28, respectively. The issuer had 18,153,090 shares of common stock outstanding, providing context for the scale of these transactions.
Outset Medical stockholder Marc Nash filed a notice of proposed sale under Rule 144. He plans to sell 980 shares of common stock through Morgan Stanley Smith Barney LLC on or about 01/21/2026, with an aggregate market value of $4,876.11. The shares are listed on NASDAQ, and the issuer had 18,153,090 shares outstanding at the time stated.
The securities to be sold were acquired on 01/17/2026 via settlement of 14,839 vested restricted stock units as equity compensation for services rendered. Over the prior three months, Nash sold additional common shares, including 247 shares for $1,136.20, 108 shares for $461.16, and 5,375 shares for $27,520.00. By signing the notice, the seller represents that he is not aware of undisclosed material adverse information about the issuer.
OM insider John Brottem has filed a Form 144 indicating an intention to sell 1,180 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ around 01/21/2026. The aggregate market value of these shares is listed as $5,913.82, compared with 18,153,090 shares of common stock outstanding. The shares to be sold stem from equity compensation: on 01/17/2026, Brottem acquired 17,997 shares via settlement of vested restricted stock units as payment for services.
Over the prior three months, Brottem has sold additional OM common stock, including 388 shares for $1,784.80 on 11/17/2025, 244 shares for $956.48 on 01/07/2026, and 9,314 shares for $47,682.76 on 01/20/2026. By signing the notice, the seller represents that he is not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
A holder of common stock in OM has filed a notice of proposed sale under Rule 144. The filer plans to sell 5,375 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of 27,520.00, on or about 01/20/2026 on the NASDAQ market. The seller reports that 18,153,090 shares of this class of common stock are outstanding.
The securities to be sold were acquired on 01/17/2026 via settlement of vested restricted stock units granted by the issuer as equity compensation for services rendered, totaling 14,839 shares. Over the prior three months, the same person sold smaller amounts of common stock, including 247 shares on 11/17/2025 for gross proceeds of 1,136.20 and 108 shares on 01/07/2026 for gross proceeds of 461.16.
Outset Medical insider plans Rule 144 stock sale. A holder of Outset Medical (symbol OM) common stock, identified as Leslie Trigg, filed notice to sell 11,794 shares through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of 60,385.28. The filing states that 18,153,090 shares of common stock were outstanding. The shares to be sold come from 32,552 shares of common stock acquired on 01/17/2026 through settlement of vested restricted stock units as equity compensation for services rendered. In the past three months, the same seller reported two sales totaling 2,711 shares of common stock, generating combined gross proceeds of 11,878.25.